TRIGLIDE patient counseling information

Jump to navigation Jump to search


Fenofibrate
ANTARA® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
TRIGLIDE ® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Fenofibrate
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Patient Counseling Information

Patients should be advised:

  • of the potential benefits and risks of Triglide.
  • not to use Triglide if there is a known hypersensitivity to fenofibrate or fenofibric acid.
  • of medications that should not be taken in combination with Triglide.

that if they are taking coumarin anticoagulants, Triglide may increase their anti-coagulant effect, and increased monitoring may be necessary.

  • to inform their physician of all medications, supplements, and herbal preparations they are taking and any change in their medical condition.
  • to inform a physician prescribing a new medication, that they are taking Triglide.
  • to continue to follow an appropriate lipid-modifying diet while taking Triglide.
  • to take Triglide once daily at the prescribed dose, swallowing each tablet whole.
  • to inform their physician of any muscle pain, tenderness, or weakness; onset of abdominal pain; or any other new symptoms.
  • to return to their physician’s office for routine monitoring.

Distributed by: Shionogi Inc. Florham Park, NJ 07932

Manufactured by: Aenova France SAS, 38291 Saint-Quentin-Fallavier, France

Made in France

TRI-PI-03

Rev. 01/2013

© Shionogi Inc. All rights reserved.[1]

Manufactured for:

Lupin Pharma

Baltimore, Maryland 21202

United States.

Manufactured by:

Lupin Limited

Goa - 403 722

INDIA.

Address Medical Inquiries to:

Lupin Pharma Medical Inquiries

111 South Calvert Street, 21st Floor

Baltimore, MD 21202

or Call: 1-800-399-2561

October 2013 ID: 235480[2]

References

  1. "TRIGLIDE (FENOFIBRATE) TABLET [SHIONOGI INC.]". Retrieved 12 February 2014.
  2. "ANTARA (FENOFIBRATE) CAPSULE [LUPIN PHARMA]". Retrieved 12 February 2014.

Template:Lipid modifying agents